Demographic and clinical characteristics of CHC and POC users among patients with SCD
| Characteristic . | CHC . | POC . | P . |
|---|---|---|---|
| Unique patients | 3197 | 3976 | |
| Mo, continuous enrollment, median, (IQR) | 72 (36-117) | 78 (41-120) | <.001 |
| SCD claims, median (IQR) | 19 (6-79) | 36 (8-134) | <.001 |
| Race-ethnicity, n (%) | <.001 | ||
| Black, non-Hispanic | 2198 (68.8) | 2856 (71.8) | |
| Hispanic | 151 (4.7) | 150 (3.8) | |
| White, non-Hispanic | 120 (3.8) | 98 (2.5) | |
| Asian | 34 (1.1) | 16 (0.4) | |
| Multiracial | 11 (0.3) | 16 (0.4) | |
| Other∗ /unknown | 683 (21.3) | 840 (21.1) | |
| Age at initial contraceptive prescription, median (IQR), y | 21.8 (18.3-27.2) | 22.5 (18.7-28.2) | <.001 |
| Age group, median (IQR) | <.001 | ||
| 12-18 y | 1014 (31.7) | 1087 (27.3) | |
| 19-26 y | 1356 (42.4) | 1752 (44.1) | |
| 27-34 y | 604 (18.9) | 777 (19.5) | |
| 35-44 y | 223 (7.0) | 360 (9.1) | |
| Sickle cell genotype, n (%) | <.001 | ||
| Hb SS | 1967 (61.5) | 2730 (68.7) | |
| Hb SC | 324 (10.1) | 407 (10.2) | |
| Hb Sβ0/+ | 385 (12.0) | 366 (9.2) | |
| Nonspecific SCD | 521 (16.3) | 473 (11.9) | |
| SCD severity, n (%) | <.001 | ||
| High | 373 (11.7) | 675 (17.0) | |
| Low | 2824 (88.3) | 3301 (83.0) | |
| Comorbid conditions, n (%) | |||
| Obesity | 168 (5.3) | 198 (5.0) | .599 |
| Smoking | 111 (3.5) | 206 (5.2) | <.001 |
| Diabetes | 97 (3.0) | 103 (2.6) | .257 |
| Hypertension | 231 (7.2) | 366 (9.2) | .003 |
| Hyperlipidemia | 62 (1.9) | 72 (1.8) | .690 |
| Cancer | 56 (1.8) | 63 (1.6) | .582 |
| Characteristic . | CHC . | POC . | P . |
|---|---|---|---|
| Unique patients | 3197 | 3976 | |
| Mo, continuous enrollment, median, (IQR) | 72 (36-117) | 78 (41-120) | <.001 |
| SCD claims, median (IQR) | 19 (6-79) | 36 (8-134) | <.001 |
| Race-ethnicity, n (%) | <.001 | ||
| Black, non-Hispanic | 2198 (68.8) | 2856 (71.8) | |
| Hispanic | 151 (4.7) | 150 (3.8) | |
| White, non-Hispanic | 120 (3.8) | 98 (2.5) | |
| Asian | 34 (1.1) | 16 (0.4) | |
| Multiracial | 11 (0.3) | 16 (0.4) | |
| Other∗ /unknown | 683 (21.3) | 840 (21.1) | |
| Age at initial contraceptive prescription, median (IQR), y | 21.8 (18.3-27.2) | 22.5 (18.7-28.2) | <.001 |
| Age group, median (IQR) | <.001 | ||
| 12-18 y | 1014 (31.7) | 1087 (27.3) | |
| 19-26 y | 1356 (42.4) | 1752 (44.1) | |
| 27-34 y | 604 (18.9) | 777 (19.5) | |
| 35-44 y | 223 (7.0) | 360 (9.1) | |
| Sickle cell genotype, n (%) | <.001 | ||
| Hb SS | 1967 (61.5) | 2730 (68.7) | |
| Hb SC | 324 (10.1) | 407 (10.2) | |
| Hb Sβ0/+ | 385 (12.0) | 366 (9.2) | |
| Nonspecific SCD | 521 (16.3) | 473 (11.9) | |
| SCD severity, n (%) | <.001 | ||
| High | 373 (11.7) | 675 (17.0) | |
| Low | 2824 (88.3) | 3301 (83.0) | |
| Comorbid conditions, n (%) | |||
| Obesity | 168 (5.3) | 198 (5.0) | .599 |
| Smoking | 111 (3.5) | 206 (5.2) | <.001 |
| Diabetes | 97 (3.0) | 103 (2.6) | .257 |
| Hypertension | 231 (7.2) | 366 (9.2) | .003 |
| Hyperlipidemia | 62 (1.9) | 72 (1.8) | .690 |
| Cancer | 56 (1.8) | 63 (1.6) | .582 |
P values result from χ2 or Wilcoxon rank-sum tests.
Other includes American Indian and Hawaiian or Pacific Islander.